EFFECT OF SGLT-2 INHIBITORS ON CARDIOVASCULAR OUTCOMES: REVIEW OF RESULTS OF CVD-REAL TRIAL


M.B. Antsiferov

SBHCI "Endocrinological Dispensary" of Moscow Healthcare Department
The article presents a review of the results of real-world international retrospective cohort trial, CVD-REAL, comparing the efficacy of various of sodium-glucose linked transporter-2 (SGLT-2) inhibitors with other antidiabetic drugs in regard to cardiovascular outcomes in patients with type 2 diabetes mellitus (DM2). It is noted that this study supplements the already available results of randomized clinical trials, and indicates the potential of early prescription of SGLT-2 inhibitors for DM2 patients. Studies with a longer follow-up period are required to confirm the long-term and persistent effects of these drugs.

About the Autors


Corresponding author: М.B Antsiferov – MD, Prof., Chief Physician of SBHCI «Endocrinological Dispensary» of Moscow Healthcare Department; tel. 8(499)246-61-75


Similar Articles


Бионика Медиа